We maintain our BUY recommendation with a price target of $2.04 as the company moves rapidly towards commercialisation of its first cardiac catheters. We expect CXD to apply to the TGA and European authorities in the near term for marketing approval of its diagnostic cardiac catheters in the short term. Plant expansion is going according to plan and we believe the company should be able to begin sales by the end of June 2006. The company already has a marketing and distribution agreement in place for the UK market and we expect other agreements for Europe to be forthcoming.
CXD Price at posting:
0.0¢ Sentiment: None Disclosure: Not Held